Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Operating Leases (2019 - 2024)

Solid Biosciences' Operating Leases history spans 6 years, with the latest figure at $21.6 million for Q3 2024.

  • For Q3 2024, Operating Leases fell 6.67% year-over-year to $21.6 million; the TTM value through Sep 2024 reached $21.6 million, down 6.67%, while the annual FY2023 figure was $22.7 million, 6.47% down from the prior year.
  • Operating Leases for Q3 2024 was $21.6 million at Solid Biosciences, down from $22.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $24.5 million in Q2 2022 and bottomed at $70000.0 in Q1 2022.
  • The 5-year median for Operating Leases is $21.6 million (2024), against an average of $13.1 million.
  • The largest annual shift saw Operating Leases plummeted 96.46% in 2022 before it soared 34060.0% in 2023.
  • A 5-year view of Operating Leases shows it stood at $2.4 million in 2020, then plummeted by 88.63% to $275000.0 in 2021, then skyrocketed by 8728.73% to $24.3 million in 2022, then decreased by 6.47% to $22.7 million in 2023, then decreased by 4.69% to $21.6 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Operating Leases are $21.6 million (Q3 2024), $22.1 million (Q2 2024), and $22.5 million (Q1 2024).